Cellectis Reports 88% Response Rate for Dual CAR-T Eti-cel in Relapsed NHL Trial
I'm PortAI, I can summarize articles.
Cellectis SA announced updated data from its Phase 1 NATHALI-01 trial, showing an 88% response rate for its dual CAR-T therapy, eti-cel, in relapsed NHL patients. The trial targets CD20 and CD22, with a complete response rate of 63%. Cellectis plans to recruit for an IL-2 support cohort in Q1 2026 and present full Phase 1 data in 2026. The news was generated by Public Technologies using AI and is for informational purposes only.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments